2024
Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System.
Shah V, Peters A, Umpierrez G, Sherr J, Akturk H, Aleppo G, Bally L, Cengiz E, Cinar A, Dungan K, Fabris C, Jacobs P, Lal R, Mader J, Masharani U, Prahalad P, Schmidt S, Zijlstra E, Ho C, Ayers A, Tian T, Aaron R, Klonoff D. Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System. Journal Of Diabetes Science And Technology 2024, 19322968241291512. PMID: 39517127, DOI: 10.1177/19322968241291512.Peer-Reviewed Original ResearchGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1RA therapyGLP-1RAGLP-1RAsType 1 diabetesReceptor agonistsAdjunctive therapyAbsence of randomized controlled trialsIncreasing prevalence of obesityUS Food and Drug AdministrationRisk of severe hypoglycemiaEffective adjunctive therapyPrevalence of obesityTreatment of T1DFood and Drug AdministrationRandomized controlled trialsDiabetic ketoacidosisAdjunctive treatmentMetabolic outcomesSevere hypoglycemiaAutomated insulin deliveryConsensus reportDrug AdministrationTherapyPerioperative Management of Adult Patients with Diabetes Wearing Devices: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Expert Consensus Statement
Oprea A, Kalra S, Duggan E, Russell L, Urman R, Abdelmalak B, Patel P, Pfeifer K, Grant P, Charitou M, Mendez C, Sherr J, Umpierrez G, Klonoff D. Perioperative Management of Adult Patients with Diabetes Wearing Devices: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Expert Consensus Statement. Journal Of Clinical Anesthesia 2024, 99: 111627. PMID: 39388833, DOI: 10.1016/j.jclinane.2024.111627.Peer-Reviewed Original ResearchPsychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes
MacLeish S, Hood K, Polonsky W, Wood J, Bode B, Forlenza G, Laffel L, Buckingham B, Criego A, Schoelwer M, DeSalvo D, Sherr J, Hansen D, Conroy L, Huyett L, Vienneau T, Ly T, Group F. Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes. Diabetes Obesity And Metabolism 2024, 26: 5569-5579. PMID: 39300963, DOI: 10.1111/dom.15906.Peer-Reviewed Original ResearchPsychosocial outcomesSleep qualityEvaluate psychosocial outcomesPittsburgh Sleep Quality Index total scoreWell-beingType 1 diabetesSatisfaction survey scoresYoung childrenBurden caregiversAid useOverall sleep qualityAutomated insulin deliverySystem usabilityCaregiversSurvey scoresDiabetes managementPerceived system usabilityGlycaemic outcomesTotal scoreSleep durationDelivery satisfactionGlycaemic metricsSubscalesOutcomesUnique challengesMaking diabetes technology accessible to all
Nally L, Sherr J. Making diabetes technology accessible to all. Nature Medicine 2024, 30: 1832-1833. PMID: 38918631, DOI: 10.1038/s41591-024-03082-8.Peer-Reviewed Original Research1199-P: Tackling Transition of Care of Young Adults with Type 1 Diabetes—Preliminary Findings
DIAS A, CONSIDINE E, WEYMAN K, CARR D, TICHY E, SHERR J. 1199-P: Tackling Transition of Care of Young Adults with Type 1 Diabetes—Preliminary Findings. Diabetes 2024, 73 DOI: 10.2337/db24-1199-p.Peer-Reviewed Original ResearchYoung adultsYale-New Haven Children's HospitalAdult providersKnowledge deficitsStructured visitsFeasibility studyTertiary care centerT1D durationCare centerReproductive healthRe-administeredChildren's HospitalAdultsProspective studyVisitsImpact of substancesMultidisciplinary approachDiabetesPre-transition periodTarget glycemiaProvidersHealthHospitalParticipantsSocial work950-P: Virtual and Self-Guided Omnipod 5 Automated Insulin Delivery (AID) System Onboarding—Real-World Outcomes by Training Type
BERGET C, FORLENZA G, SHERR J, DESALVO D, ALEPPO G, WILMOT E, HUYETT L, HADJIYIANNI I, MENDEZ J, CONROY L, LY T. 950-P: Virtual and Self-Guided Omnipod 5 Automated Insulin Delivery (AID) System Onboarding—Real-World Outcomes by Training Type. Diabetes 2024, 73 DOI: 10.2337/db24-950-p.Peer-Reviewed Original Research270-OR: Real-World Outcomes with the Omnipod 5 Automated Insulin Delivery (AID) System for >7,500 Users with High HbA1c (>9%) at Baseline
FORLENZA G, SHERR J, DESALVO D, ALEPPO G, WILMOT E, BERGET C, HUYETT L, HADJIYIANNI I, MENDEZ J, CONROY L, LY T. 270-OR: Real-World Outcomes with the Omnipod 5 Automated Insulin Delivery (AID) System for >7,500 Users with High HbA1c (>9%) at Baseline. Diabetes 2024, 73 DOI: 10.2337/db24-270-or.Peer-Reviewed Original Research240-OR: Longitudinal Assessment of Glycemia and Severe Hypoglycemia among Adults with Type 1 Diabetes—An Online Survey
SHERR J, HAGAN K, BHAK R, PETER M, NGUYEN H, WANG C, PAKALAPATI T, SHERWOOD J, GUPTA T, GAGLIA J, CORNELIUS E, CHAPMAN K, WOLF W, PETTUS J. 240-OR: Longitudinal Assessment of Glycemia and Severe Hypoglycemia among Adults with Type 1 Diabetes—An Online Survey. Diabetes 2024, 73 DOI: 10.2337/db24-240-or.Peer-Reviewed Original ResearchFollow-up surveySevere hypoglycemic eventsImpaired awareness of hypoglycemiaOnline surveyT1D Exchange RegistryProportion of respondentsT1D careFollow-upEligible individualsHbA1c < 7%Diabetes technologyLongitudinal trendsCGM useHbA1c targetLongitudinal assessmentInsulin delivery methodsHbA1cAwareness of hypoglycemiaSurveyParticipantsImpaired awarenessAdultsT1DRespondentsHypoglycemic events326-OR: Activity Feature Attenuates Drop in Glucose for Individuals with Type 1 Diabetes Using Omnipod 5 Automated Insulin Delivery System
TURNER L, SHERR J, ZAHARIEVA D, BARAN J, BODE B, BROWN S, BZDICK S, MEI CHURCH M, HANSEN D, KINGMAN R, LAFFEL L, SHAH V, STONE S, VIENNEAU T, HUYETT L, DUMAIS B, LY T, RIDDELL M, 5 EXERCISE RESEARCH GROUP O. 326-OR: Activity Feature Attenuates Drop in Glucose for Individuals with Type 1 Diabetes Using Omnipod 5 Automated Insulin Delivery System. Diabetes 2024, 73 DOI: 10.2337/db24-326-or.Peer-Reviewed Original ResearchGeneralized estimating equationsInternational Society for Pediatric and Adolescent DiabetesActivity sessionsEstimating equationsType 1 diabetesExerciseAdolescent DiabetesAF-30Glucose declineDeliveryInsulin deliveryInsuletSessionsDelivery systemInsulin delivery systemsDiabetesAutomated deliveryOmnipodRiskGlucoseT1DPeopleDigital Gaming and Exercise Among Youth With Type 1 Diabetes: Cross-Sectional Analysis of Data From the Type 1 Diabetes Exercise Initiative Pediatric Study
Patton S, Gal R, Bergford S, Calhoun P, Clements M, Sherr J, Riddell M. Digital Gaming and Exercise Among Youth With Type 1 Diabetes: Cross-Sectional Analysis of Data From the Type 1 Diabetes Exercise Initiative Pediatric Study. JMIR Pediatrics And Parenting 2024, 7: e57198. PMID: 38889077, PMCID: PMC11186795, DOI: 10.2196/57198.Peer-Reviewed Original ResearchExercise sessionsPhysical activityMinutes of physical activityLevels of physical activityRegular physical activityType 1 diabetesCross-sectional analysisDigital gamesHealthy lifestyleActive wearablesGame sessionsExerciseInsulin useNondigital gamesDaily activitiesPediatric studiesSessionsContext of youthDisease statusYouthT1DCharacteristics of digital gamesInsulin pumpObservation periodContinuous glucose monitoringPredicting Hypoglycemia and Hyperglycemia Risk During and After Activity for Adolescents with Type 1 Diabetes
Bergford S, Riddell M, Gal R, Patton S, Clements M, Sherr J, Calhoun P. Predicting Hypoglycemia and Hyperglycemia Risk During and After Activity for Adolescents with Type 1 Diabetes. Diabetes Technology & Therapeutics 2024, 26: 728-738. PMID: 38669475, DOI: 10.1089/dia.2024.0061.Peer-Reviewed Original ResearchRepeated measures logistic regressionPhysically active adolescentsHyperglycemia riskType 1 diabetesMeasures logistic regressionComposite riskAcute glucose responseGlucose rateWearing continuous glucose monitoringContinuous glucose monitoringReceiver operating characteristic curveArea under the receiver operating characteristic curveRisk of hypoglycemiaLogistic regressionActive adolescentsHbA1c levelsActivity startExerciseAdolescentsRiskCharacteristic curveHypoglycemiaGlucose responseHyperglycemiaT1DResponse to: MiniMed 780G System Outperforms Other Automated Insulin Systems Due to Algorithm Design, Not Bias—Response to Inaccurate Allegations
Forlenza G, Sherr J. Response to: MiniMed 780G System Outperforms Other Automated Insulin Systems Due to Algorithm Design, Not Bias—Response to Inaccurate Allegations. Diabetes Technology & Therapeutics 2024, 26: 785-786. PMID: 38512386, DOI: 10.1089/dia.2024.0125.Peer-Reviewed Original ResearchExploring Factors That Influence Postexercise Glycemia in Youth With Type 1 Diabetes in the Real World: The Type 1 Diabetes Exercise Initiative Pediatric (T1DEXIP) Study.
Sherr J, Bergford S, Gal R, Clements M, Patton S, Calhoun P, Beaulieu L, Riddell M. Exploring Factors That Influence Postexercise Glycemia in Youth With Type 1 Diabetes in the Real World: The Type 1 Diabetes Exercise Initiative Pediatric (T1DEXIP) Study. Diabetes Care 2024, 47: 849-857. PMID: 38412033, DOI: 10.2337/dc23-2212.Peer-Reviewed Original ResearchParticipants self-reported physical activitySelf-reported physical activityPostexercise recovery periodEvent-level factorsExercise sessionsPhysical activitySedentary dayExercise studiesSupport exerciseExerciseDelivery modalitiesSD ageType 1 diabetesHemoglobin A1cPostexercisePump useShorter disease durationDecision support toolGlucose dataRecovery periodHbA1cDisease durationHypoglycemia riskInsulin delivery modalityHypoglycemia ratesGlycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod® 5 Automated Insulin Delivery System
DeSalvo D, Bode B, Forlenza G, Laffel L, Buckingham B, Criego A, Schoelwer M, MacLeish S, Sherr J, Hansen D, Ly T. Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod® 5 Automated Insulin Delivery System. Diabetes Technology & Therapeutics 2024, 26: 383-393. PMID: 38277156, DOI: 10.1089/dia.2023.0506.Peer-Reviewed Original ResearchType 1 diabetesExtension phaseEpisodes of diabetic ketoacidosisEpisodes of severe hypoglycemiaLong-term safetyLong-term useStandard therapyDiabetic ketoacidosisAutomated insulin deliverySevere hypoglycemiaYoung childrenConclusion:</i></b>Continuous glucose monitoring metricsExtension studyMethods:</i></b>MonthsGlycemic outcomesTarget rangeTrialsOmnipodHbA1cInsulin deliveryDelivery systemInsulin delivery systemsEpisodesReal-World Evidence of Omnipod® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes
Forlenza G, DeSalvo D, Aleppo G, Wilmot E, Berget C, Huyett L, Hadjiyianni I, Méndez J, Conroy L, Ly T, Sherr J. Real-World Evidence of Omnipod® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes. Diabetes Technology & Therapeutics 2024, 26: 514-525. PMID: 38375861, DOI: 10.1089/dia.2023.0578.Peer-Reviewed Original ResearchGlucose targetsType 1 diabetesSubgroup analysisGlycemic outcomesReal-world evidenceMultiple daily injectionsYounger age groupsBaseline characteristicsDaily injectionsRetrospective analysisClinical trialsMedian percentageAge groupsResults:</i></b>OmnipodDelivery systemOutcomesInsulin delivery systemsT1DSubgroupsDiverse sampleReal-World Evidence of Automated Insulin Delivery System Use
Considine E, Sherr J. Real-World Evidence of Automated Insulin Delivery System Use. Diabetes Technology & Therapeutics 2024, 26: 53-65. PMID: 38377315, PMCID: PMC10890954, DOI: 10.1089/dia.2023.0442.Peer-Reviewed Original ResearchConceptsGlucose management indicatorAid useRetrospective real-world studyMode of insulin deliveryGlycemic benefitsFollow-up periodTrial findingsFood and Drug AdministrationStandard of careReal-world studyInsulin deliveryType 1 diabetesNonpregnant individualsPivotal trialsRetrospective analysisPrimary outcomeHemoglobin A1cConclusion:</i></b>Drug AdministrationInclusion criteriaHbA1cGlycemic outcomesSystematic reviewResults:</i></b>Target rangeSevere Hypoglycemia and Impaired Awareness of Hypoglycemia Persist in People With Type 1 Diabetes Despite Use of Diabetes Technology: Results From a Cross-sectional Survey
Sherr J, Laffel L, Liu J, Wolf W, Bispham J, Chapman K, Finan D, Titievsky L, Liu T, Hagan K, Gaglia J, Chandarana K, Bergenstal R, Pettus J. Severe Hypoglycemia and Impaired Awareness of Hypoglycemia Persist in People With Type 1 Diabetes Despite Use of Diabetes Technology: Results From a Cross-sectional Survey. Diabetes Care 2024, 47: 941-947. PMID: 38295397, PMCID: PMC11116910, DOI: 10.2337/dc23-1765.Peer-Reviewed Original ResearchImpaired awareness of hypoglycemiaSevere hypoglycemic eventsType 1 diabetesGlycemic targetsContinuous glucose monitoringInsulin delivery modalityDiabetes technologyImproved treatment strategiesAwareness of hypoglycemiaImpaired awarenessU.S. RESEARCH DESIGNAdvanced diabetes technologiesProportion of participantsCross-sectional surveySubgroup analysisSevere hypoglycemiaTreatment strategiesAutomated insulin deliveryImpact of continuous glucose monitoringGlycemic metricsHypoglycemic eventsObservational studyProportion of peopleResearch designInsulin deliveryPostprandial Glucose Variability Following Typical Meals in Youth Living with Type 1 Diabetes
Patton S, Bergford S, Sherr J, Gal R, Calhoun P, Clements M, Riddell M, Martin C. Postprandial Glucose Variability Following Typical Meals in Youth Living with Type 1 Diabetes. Nutrients 2024, 16: 162. PMID: 38201991, PMCID: PMC10781146, DOI: 10.3390/nu16010162.Peer-Reviewed Original ResearchConceptsGlycemic variabilityGlucose variabilityType 1Continuous glucose monitoringPediatric studiesCarbohydrate intakeDay observation periodMacronutrient intakeDietary guidelinesPhysical activityExercise intensityT1DGlucose monitoringObservation periodTypical mealMeal contentMealIntakeCoefficient of variationAssociationMacronutrient contentMore carbohydratesCliniciansLarge sample
2023
A narrative commentary about interoperability in medical devices and data used in diabetes therapy from an academic EU/UK/US perspective
Jendle J, Adolfsson P, Choudhary P, Dovc K, Fleming A, Klonoff D, Mader J, Oliver N, Sherr J, Šoupal J, Heinemann L. A narrative commentary about interoperability in medical devices and data used in diabetes therapy from an academic EU/UK/US perspective. Diabetologia 2023, 67: 236-245. PMID: 38041737, PMCID: PMC10789828, DOI: 10.1007/s00125-023-06049-5.Peer-Reviewed Original ResearchLimitations of interoperabilityData-sharing protocolsData interoperabilitySecure integrationElectronic health recordsData ownershipInteroperabilitySeamless integrationTransparent handlingData handlingHealth recordsMedical devicesPractical challengesKey issuesTransparent frameworkPrivacyFrameworkDevicesCritical aspectsDifferent sourcesIntegrationProtocolNeeds of peopleLegal issuesIssuesTwo Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes
Criego A, Carlson A, Brown S, Forlenza G, Bode B, Levy C, Hansen D, Hirsch I, Bergenstal R, Sherr J, Mehta S, Laffel L, Shah V, Bhargava A, Weinstock R, MacLeish S, DeSalvo D, Jones T, Aleppo G, Buckingham B, Ly T, Group F. Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2023, 26: 11-23. PMID: 37850941, PMCID: PMC10794844, DOI: 10.1089/dia.2023.0364.Peer-Reviewed Original ResearchConceptsAdolescents/adultsPivotal trialsInsulin delivery systemsSingle-arm multicenter trialYears of useClinical trial registrationType 1 diabetesLong-term safetyMonths of useLong-term useDiabetic ketoacidosisMulticenter trialSevere hypoglycemiaTRIAL REGISTRATIONGlycemic outcomesType 1Delivery systemExtension phaseMonthsTrialsTarget rangeAdultsHbA1cChildrenEpisodes